# Genmab (stock symbol: GMAB) Logo in transparent PNG and SVG formats

## Genmab Logo large

### Genmab Logo large Download PNG (33.95 KB)

![Genmab Logo large Download PNG (33.95 KB)](/img/orig/GMAB_BIG-f90e1b53.png)

### Genmab Logo large Download SVG (10.88 KB)

![Genmab Logo large Download SVG (10.88 KB)](/img/orig/GMAB_BIG-f369ad26.svg)

## Genmab Logo icon format

### Genmab Logo icon format Download PNG (35.21 KB)

![Genmab Logo icon format Download PNG (35.21 KB)](/img/orig/GMAB-3e782be2.png)

### Genmab Logo icon format Download SVG (1.43 KB)

![Genmab Logo icon format Download SVG (1.43 KB)](/img/orig/GMAB-00ef1e0b.svg)

## Genmab Logo large for dark backgrounds

### Genmab Logo large for dark backgrounds Download PNG (20.65 KB)

![Genmab Logo large for dark backgrounds Download PNG (20.65 KB)](/img/orig/GMAB_BIG.D-43445778.png)

### Genmab Logo large for dark backgrounds Download SVG (10.86 KB)

![Genmab Logo large for dark backgrounds Download SVG (10.86 KB)](/img/orig/GMAB_BIG.D-8d55e4a2.svg)

## Genmab Logo icon format for dark backgrounds

### Genmab Logo icon format for dark backgrounds Download PNG (21.02 KB)

![Genmab Logo icon format for dark backgrounds Download PNG (21.02 KB)](/img/orig/GMAB.D-09f25749.png)

### Genmab Logo icon format for dark backgrounds Download SVG (1.41 KB)

![Genmab Logo icon format for dark backgrounds Download SVG (1.41 KB)](/img/orig/GMAB.D-e4bc2dc3.svg)

## About Genmab

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

1. Website domain: genmab.com
2. Employees: 1560
3. Marketcap: $26.74 Billion USD


## Categories
- [x] ðŸ‡©ðŸ‡° Denmark
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
